EP0506893A4 - Diagnosis and treatment of diseases - Google Patents

Diagnosis and treatment of diseases

Info

Publication number
EP0506893A4
EP0506893A4 EP91905252A EP91905252A EP0506893A4 EP 0506893 A4 EP0506893 A4 EP 0506893A4 EP 91905252 A EP91905252 A EP 91905252A EP 91905252 A EP91905252 A EP 91905252A EP 0506893 A4 EP0506893 A4 EP 0506893A4
Authority
EP
European Patent Office
Prior art keywords
diagnosis
diseases
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP91905252A
Other languages
English (en)
Other versions
EP0506893A1 (en
Inventor
James L Urban
Dennis M Zaller
Leroy E Hood
Stevens S Beall
Patrick Concannon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
California Institute of Technology CalTech
Original Assignee
California Institute of Technology CalTech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Institute of Technology CalTech filed Critical California Institute of Technology CalTech
Publication of EP0506893A1 publication Critical patent/EP0506893A1/en
Publication of EP0506893A4 publication Critical patent/EP0506893A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C12Q1/683—Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP91905252A 1989-12-29 1990-12-31 Diagnosis and treatment of diseases Withdrawn EP0506893A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US459065 1983-01-19
US45906589A 1989-12-29 1989-12-29
US51738090A 1990-05-01 1990-05-01
US517380 1990-05-01

Publications (2)

Publication Number Publication Date
EP0506893A1 EP0506893A1 (en) 1992-10-07
EP0506893A4 true EP0506893A4 (en) 1996-09-25

Family

ID=27039224

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91905252A Withdrawn EP0506893A4 (en) 1989-12-29 1990-12-31 Diagnosis and treatment of diseases

Country Status (6)

Country Link
EP (1) EP0506893A4 (ja)
JP (1) JPH05504409A (ja)
KR (1) KR920703095A (ja)
AU (1) AU660606B2 (ja)
CA (1) CA2072356A1 (ja)
WO (1) WO1991009623A1 (ja)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413516B1 (en) * 1989-03-21 2002-07-02 The Immune Response Corporation Peptides and methods against psoriasis
US5776459A (en) * 1989-07-19 1998-07-07 Connetics Corporation TCR V beta 5 peptides
IL97709A (en) * 1990-03-30 2005-05-17 Brigham & Womens Hospital Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis
CA2081672A1 (en) * 1990-05-01 1991-11-02 Lawrence Steinman T-cell receptor variable transcripts as disease related markers
US5747036A (en) * 1991-08-28 1998-05-05 Brigham & Women's Hospital Methods and compositions for detecting and treating a subset of human patients having an autoimmune disease
US5445940A (en) * 1991-08-28 1995-08-29 Brigham & Women's Hospital Methods and compositions for detecting and treating a subset of human patients having an autoimmune disease
JPH06511241A (ja) * 1991-09-23 1994-12-15 ジェネンテク，インコーポレイテッド 自己免疫疾患の診断および治療
US5552300A (en) * 1994-01-13 1996-09-03 T Cell Sciences, Inc. T cell antigen receptor V region proteins and methods of preparation thereof
US6034064A (en) * 1995-04-07 2000-03-07 Hoechst Pharmaceuticals & Chemicals K.K. Peptides and therapeutic agent for autoimmune diseases containing the same
JPH08333390A (ja) * 1995-04-07 1996-12-17 Hoechst Japan Ltd ペプチド及びそれからなる自己免疫疾患治療剤
DE19534170C1 (de) * 1995-09-14 1997-04-10 Univ Tuebingen Rekombinantes Polypeptid basierend auf der Primärsequenz der invarianten Kette mit mindestens einer Primärsequenz von einem spezifischen T-Zellepitop oder eines Proteinderivats und dieses rekombinante Polypeptid kodierende Nukleinsäuren
US6087096A (en) * 1995-11-13 2000-07-11 Dau; Peter C. Method of intrafamily fragment analysis of the T cell receptor α and β chain CDR3 regions
AU758455B2 (en) * 1997-07-21 2003-03-20 Arpi Matossian-Rogers Ligands, including antibodies, showing reactivity against endocrine cells
GB0128153D0 (en) * 2001-11-23 2002-01-16 Bayer Ag Profiling of the immune gene repertoire
KR20040001552A (ko) * 2002-06-28 2004-01-07 주식회사 인투젠 디엔에이 결합 단백질 비에 대한 자가항체에 결합할 수있는 단백질을 유효 성분으로 함유하는 전신성 경화증진단용 조성물, 이를 이용한 상기 자가항체의 검출 방법및 전신성 경화증 진단 방법
US20120296675A1 (en) * 2006-02-13 2012-11-22 Silverman David G Method and System for Assessing, Quantifying, Coding & Communicating a Patient's Health and Perioperative Risk
US10796801B2 (en) 2006-02-13 2020-10-06 David G. Silverman Method and system for assessing, quantifying, coding and communiicating patient's health and perioperative risk
EP3392270B1 (en) 2011-09-15 2020-08-26 The United States of America, as Represented by the Secretary Department of Health and Human Services T cell receptors recognizing hla-a1- or hla-cw7-restricted mage

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713332A (en) * 1984-01-13 1987-12-15 The Ontario Cancer Institute T cell specific CDNA clone
EP0296786A1 (en) * 1987-06-23 1988-12-28 The Board Of Trustees Of The Leland Stanford Junior University T-cell receptor gene located within alpha locus and dna constructions
US4886743A (en) * 1985-04-24 1989-12-12 California Institute Of Technology Diagnostic reagents based on unique sequences within the variable region of the T cell receptor and uses thereof
WO1992013949A1 (fr) * 1991-02-08 1992-08-20 Roussel-Uclaf Sequences nucleotidiques codant pour des regions variables de chaines alpha des recepteurs des lymphocytes humains ainsi que leurs applications

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713332A (en) * 1984-01-13 1987-12-15 The Ontario Cancer Institute T cell specific CDNA clone
US4886743A (en) * 1985-04-24 1989-12-12 California Institute Of Technology Diagnostic reagents based on unique sequences within the variable region of the T cell receptor and uses thereof
EP0296786A1 (en) * 1987-06-23 1988-12-28 The Board Of Trustees Of The Leland Stanford Junior University T-cell receptor gene located within alpha locus and dna constructions
WO1992013949A1 (fr) * 1991-02-08 1992-08-20 Roussel-Uclaf Sequences nucleotidiques codant pour des regions variables de chaines alpha des recepteurs des lymphocytes humains ainsi que leurs applications

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BARTH R K ET AL: "THE MURINE T CELL RECEPTOR USES A LIMITED REPERTOIRE OF EXPRESSED V-BETA GENE SEGMENTS", NATURE (LONDON), 316 (6028). 1985. 517-523., XP002008909 *
IKUTA K ET AL: "LOW FREQUENCY OF SOMATIC MUTATION IN BETA-CHAIN VARIABLE REGION GENES OF HUMAN T CELL RECEPTORS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 82 (22). 1985. 7701-7705., XP002008913 *
LEIDEN J M ET AL: "GENERATION OF DIVERSITY OF THE BETA CHAIN OF THE HUMAN T LYMPHOCYTE RECEPTOR FOR ANTIGEN", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 83 (12). 1986. 4456-4460., XP002008910 *
M.H.KLEIN ET AL.: "Diversity and structure of human T-cell receptor alpha chain variable region genes", PROC.NAT.ACAD.SCI.USA, vol. 84, 1987, pages 6884 - 6888, XP002008907 *
See also references of WO9109623A1 *
TUNNACLIFFE A ET AL: "SEQUENCE AND EVOLUTION OF THE HUMAN T CELL ANTIGEN RECEPTOR BETA-CHAIN GENES", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 82 (15). 1985. 5068-5072., XP002008911 *
Y.YOSHIKAI ET AL.: "Sequences and repertoire of human T cell receptor alpha chain variable region genes in mature T lymphocytes", J.EXP. MED., vol. 164, 1986, pages 90 - 103, XP002008908 *
YOSHIKAI Y ET AL: "ORGANIZATION AND SEQUENCES OF THE VARIABLE JOINING AND CONSTANT REGION GENES OF THE HUMAN T CELL RECEPTOR ALPHA-CHAIN", NATURE (LONDON), 316 (6031). 1985. 837-840., XP002008912 *

Also Published As

Publication number Publication date
JPH05504409A (ja) 1993-07-08
WO1991009623A1 (en) 1991-07-11
KR920703095A (ko) 1992-12-17
AU7347091A (en) 1991-07-24
AU660606B2 (en) 1995-07-06
CA2072356A1 (en) 1991-06-30
EP0506893A1 (en) 1992-10-07

Similar Documents

Publication Publication Date Title
SG49658A1 (en) Treatment of condition and disease
KR0125921B1 (en) Method and device for the diagnosis and treatment of nasal diseases
EP0506893A4 (en) Diagnosis and treatment of diseases
GB8928934D0 (en) Treatment of birds
GB2243296B (en) Treatment of disease associated with hiv-infections
OA09658A (en) Materials and methods for the treatment of foreign tissue
EP0287361A3 (en) Treatment of allergy and composition therefor
EP0557388A4 (en) Diagnosis and treatment of multiple sclerosis
GB8719343D0 (en) Medical treatment of fish
ZA914435B (en) Treatment of disease
EP0411900A3 (en) Treatment of conditions involving excessive eating
EP0436717A4 (en) Method of treatment with medical agents
GB2220652B (en) Treatment of pastures
GB9010190D0 (en) Composition for the treatment of protozoal disease and their use
ZA936136B (en) Treatment of skin diseases
GB9216360D0 (en) Treatment of blood
GB8806116D0 (en) Treatment of skin diseases
GB8924518D0 (en) Treatment of eczema and other skin diseases
IE883282L (en) Treatment of bone diseases
GB8829366D0 (en) Treatment of disease
GB8611588D0 (en) Treatment of skin diseases
IE871907L (en) "methods for treatment of sundamaged human skin with¹retinoids"
EP0427850A4 (en) Anti-ergotypic t cells for the treatment or prevention of autoimmune diseases and methods of use thereof
IE892593L (en) Treatment of virus diseases
GB8817446D0 (en) Treatment of various blood disorders

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19920710

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19960807

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19970414

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19981020